Gan & Lee Pharmaceuticals Co., Ltd. (603087.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 69.51

From 52W high−17.77%

Volume6.64M

Market capCNY 39.11B

P/E (TTM)34.2x

P/S (TTM)10.4x

Div yield1.45%

Key dataSep 18, 2026

Open

CNY 69.51

From 52W high

−17.77%

Volume

6.64M

Market cap

CNY 39.11B

ValuationView details →

P/E (Fwd)

25.6x

EV/EBITDA

26.2x

P/E (TTM)

34.2x

RSI (14)

49.1

MomentumView details →

1D Return

−4.33%

YTD Return

+1.23%

ValuationView details →

P/E (Fwd)

25.6x

P/E (TTM)

34.2x

EV/EBITDA

26.2x

EV/Sales

9.9x

P/S (TTM)

10.4x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

75.33%

Net Margin

25.96%

EBITDA Margin

37.70%

ROE (TTM)

8.66%

ROA (TTM)

8.08%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+13.70%

EPS YoY

+23.23%

FCF YoY

—

Revenue CAGR 3Y

+33.26%

EPS CAGR 3Y

+79.35%

EBITDA YoY

—

MomentumView details →

1D Return

−4.33%

YTD Return

+1.23%

1Y Return

−2.85%

RSI (14)

49.1

vs 50D SMA

−0.51%

vs 200D SMA

+7.15%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

7.99x

Quick Ratio

6.37x

Div Yield

1.45%

Div Rate

CNY 1.00

Div Growth 1Y

+42.86%

EarningsView details →

EPS (Actual)

CNY 0.68

EPS Surprise

−10.37%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.60

Avg Surprise (4Q)

−10.37%

Rev Surprise

1.71%

Financials snapshotView financials →

Revenue (TTM)

3.95B

Net Income (TTM)

1.02B

Op. CF (TTM)

797.20M

Next earningsOct 22, 2026 →

Latest newsMore news →

Gan & Lee Pharmaceuticals received approval from China's National Medical Products Administration to conduct clinical trials of its self-developed recombinant human albumin product GLR1075 injection for cirrhotic ascites with hypoalbuminemia.2d ago

Gan & Lee Pharmaceuticals reported 2025 revenue above RMB 4 billion and net profit above RMB 1.1 billion, both record highs since its listing, according to CFO Wang Qi.9d ago

Similar companies

ResMed Inc.RMD Alcon Inc.ALC Becton, Dickinson and CompanyBDX 奕瑞科技688301.SH Medline Inc.MDLN West Pharmaceutical Services, Inc.WST Find similar companies →

Latest newsMore news →

Gan & Lee Pharmaceuticals received approval from China's National Medical Products Administration to conduct clinical trials of its self-developed recombinant human albumin product GLR1075 injection for cirrhotic ascites with hypoalbuminemia.2d ago Gan & Lee Pharmaceuticals reported 2025 revenue above RMB 4 billion and net profit above RMB 1.1 billion, both record highs since its listing, according to CFO Wang Qi.9d ago Ganli Pharmaceutical's subsidiary Ganli Pharmaceutical Shandong completed first-patient dosing in a Phase I clinical trial of GZC8072 tablets in China.13d ago